Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Parallel, Randomized, Open-label, Controlled Study of EG-301 150 mg Daily in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD

NCT05170048 is registered in ClinicalTrials.gov with Evergreen Therapeutics, Inc. as lead sponsor.

NCT NCT05170048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05170048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Parallel, Randomized, Open-label, Controlled Study of EG-301 150 mg Daily in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD
Lead sponsor
Evergreen Therapeutics, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
June 30, 2028
Enrollment
90 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-exudative (dry) age-related macular degeneration (damd)